ABSTRACT: Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases - RNA-Seq mapped and unmapped reads
Project description:Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases - WGS mapped reads
Project description:The goal of the experiment was to explore the differences in the proteomic landscape of pancreatic cancer tissues collected by the Rapid Autopsy Program at UNMC. We hypothesized the proteomic profile can reflect some of the clinical features observed in the patient, and such information can be used for the diagnosis of the disease, or assisting in the selection of treatment options in a clinical setting. The liver metastases tissue collected from 59 pancreatic cancer patients were used to explore the proteomic landscape. 56 of these patients were diagnosed with pancreatic ductal adenocarcinoma (PDAC) and 3 of them had pancreatic neuroendocrine tumors (PanNET).
Project description:This SuperSeries is composed of the following subset Series: GSE36871: Nascent-Seq Reveals Novel Features of Mouse Circadian Transcriptional Regulation [RNA-Seq] GSE36872: Nascent-Seq Reveals Novel Features of Mouse Circadian Transcriptional Regulation [Nascent-Seq] GSE36873: Nascent-Seq Reveals Novel Features of Mouse Circadian Transcriptional Regulation [StrandSpe_NascentSeq] GSE36874: Nascent-Seq Reveals Novel Features of Mouse Circadian Transcriptional Regulation [ChIP-seq] Refer to individual Series
Project description:The goal of the experiment was to explore the differences in the proteomic landscape of pancreatic cancer tissues collected by the Rapid Autopsy Program at UNMC. We hypothesized the proteomic profile can reflect some of the clinical features observed in the patient, and such information can be used for the diagnosis of the disease, or assisting in the selection of treatment options in a clinical setting. The liver metastases tissue collected from 59 pancreatic cancer patients were used to explore the proteomic landscape. 56 of these patients were diagnosed with pancreatic ductal adenocarcinoma (PDAC) and 3 of them had pancreatic neuroendocrine tumors (PanNET). The additional 9 primary tumor samples analyzed are included in this project.
Project description:Background: Mortality rates of pancreatic cancer remain high, which is mainly due to advanced disease and metastasis. We hypothesized that DNA copy number alteration are enriched in metastatic cells compared to autologous primary tumors, which may inform on cancer-related pathways possibly serving as potential targets for specific therapies. We investigated 18 pancreatic ductal adenocarcinomas, including 39 lymph node and 5 distant metastases after surgical resection. Analysis was performed with array-based comparative genomic hybridization. Results: Metastases acquire a higher frequency of CNAs with the highest in distant metastasis (OM: median=42, LNM: median=23, PT: median=17). In LNM, gains were prevalent on chromosome bands 8q11.23-q24.3, 12q14.1, 17p12.1, 21q22.12, and losses on 3p21.31, 4p14, 8p23.3-p11.21,17p12-11.2. Genes on amplified regions are involved in cancer-related pathways such as WNT-signaling, also involved in metastasis. Conclusions: Pancreatic cancers show a high degree of intratumor heterogeneity, which could lead to resistance of chemotherapy and worse outcome. ACGH analysis reveals regions preferentially gained or lost in synchronous metastases encoding for genes involved in cancer-related pathways, which could lead to novel therapeutic opportunities.
Project description:Pancreatic cancer is a devastating disease with both local invasion and distant metastasis. Identifying the genes expressed in liver metastases and signatures of metastatic progression would therefore be of particular importance as they could aid in both recurrence prediction as well as representing novel therapeutic targets. Keywords: Gene expression profiling We have performed microarray gene expression analysis of normal pancreas, primary pancreatic ductal adenocarcinoma (PDAC), normal liver and pancreatic liver metastases to identify potential therapeutic targets.
